Evercore ISI lowered the firm’s price target on Hologic (HOLX) to $76 from $81 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic enters agreement with CDC to develop ASRs
- Hologic price target lowered to $84 from $90 at UBS
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Hologic initiated with a Peer Perform at Wolfe amid near-term headwinds
- Hologic initiated with a Peer Perform at Wolfe Research